Suppr超能文献

由一种新的生殖系剪接位点变异导致的垂体巨人症。

Pituitary gigantism due to a novel germline splice-site variant.

作者信息

Lamback Elisa, Miranda Renan Lyra, Chimelli Leila, Andreiuolo Felipe, Kasuki Leandro, Wildemberg Luiz Eduardo, Gadelha Mônica R

机构信息

Neuroendocrinology Research Center, Endocrinology Section, Medical School and Hospital Universitário Clementino Fraga Filho, Universidade Federal do Rio de Janeiro, Brazil.

Neuropathology and Molecular Genetics Laboratory, Instituto Estadual do Cérebro Paulo Niemeyer, Secretaria Estadual de Saúde, Rio de Janeiro, Brazil.

出版信息

Endocr Oncol. 2024 Sep 24;4(1):e240003. doi: 10.1530/EO-24-0003. eCollection 2024 Jan 1.

Abstract

Pituitary gigantism is a rare pediatric disorder caused by excess growth hormone (GH) secretion. In almost 50% of cases, a genetic cause can be identified, with pathogenic variants in the aryl hydrocarbon receptor-interacting protein () gene being the most common. We present a case of an 11-year-old boy who exhibited progressive vision loss, associated with accelerated linear growth, and weight gain. On physical examination, he had enlarged hands, right eye amaurosis, and was already above his target height. Increased GH and IGF-I concentrations confirmed the diagnosis of pituitary gigantism. Magnetic resonance imaging showed a giant sellar lesion with supra- and para-sellar extensions. He underwent two surgeries which did not achieve a cure or visual improvement. Histopathological analysis revealed a sparsely granulated tumor, negative for somatostatin receptor type 2 (SST2) and an immunoreactivity score of 6 for somatostatin receptor type 5 (SST5). Our published artificial intelligence prediction model predicted an 83% chance of not responding to first-generation somatostatin receptor ligands. Pasireotide was therefore prescribed, and afterward cabergoline was added on. IGF-I concentrations decreased but did not normalize. We discovered a novel germline single nucleotide variant in the splicing donor region of intron 2 of the gene (NM_003977.4:c.279+1 G>A), classified as likely pathogenic according to the American College of Medical Genetics and Genomics guidelines.

摘要

垂体巨人症是一种由生长激素(GH)分泌过多引起的罕见儿科疾病。在近50%的病例中,可以确定遗传原因,其中芳烃受体相互作用蛋白()基因的致病变异最为常见。我们报告一例11岁男孩,表现为进行性视力丧失,伴有线性生长加速和体重增加。体格检查发现他双手增大、右眼失明,且已超过其目标身高。生长激素和胰岛素样生长因子-I(IGF-I)浓度升高证实了垂体巨人症的诊断。磁共振成像显示鞍区巨大病变,向鞍上和鞍旁延伸。他接受了两次手术,但未治愈,视力也未改善。组织病理学分析显示为稀疏颗粒状肿瘤,生长抑素2型受体(SST2)阴性,生长抑素5型受体(SST5)免疫反应评分为6分。我们发表的人工智能预测模型预测,对第一代生长抑素受体配体无反应的概率为83%。因此,给他开了帕西瑞肽,随后加用了卡麦角林。IGF-I浓度下降但未恢复正常。我们在基因(NM_003977.4:c.279+1 G>A)第2内含子的剪接供体区域发现了一种新的种系单核苷酸变异,根据美国医学遗传学与基因组学学会的指南,该变异被分类为可能致病。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7b50/11466259/dcd990a41187/EO-24-0003fig1.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验